Abstract:Hemostasis, thrombosis, and inflammation are tightly interconnected processes which may give rise to thrombo-inflammation, involved in infectious and non-infectious acute and chronic diseases, including cardiovascular diseases (CVD). Traditionally, due to its hemostatic role, blood coagulation is isolated from the inflammation, and its critical contribution in the progressing CVD is underrated, until the full occlusion of a critical vessel occurs. Underlying vascular injury exposes extracellular matrix to deposit platelets and inflammatory cells. Platelets being key effector cells, bridge all the three key processes (hemostasis, thrombosis, and inflammation) associated with thrombo-inflammation. Under physiological conditions, platelets remain in an inert state despite the proximity to the endothelium and other cells which are decorated with glycosaminoglycan (GAG)-rich glycocalyx (GAGs). A pathological insult to the endothelium results in an imbalanced blood coagulation system hallmarked by increased thrombin generation due to losses of anticoagulant and cytoprotective mechanisms, i.e., the endothelial GAGs enhancing antithrombin, tissue factor pathway-inhibitor (TFPI) and thrombomodulin-protein C system. Moreover, the loss of GAGs promotes the release of mediators, such as von Willebrand factor (VWF), platelet factor 4 (PF4), and P-selectin, both locally on vascular surfaces and to circulation, further enhancing the adhesion of platelets to the affected sites. Platelet-neutrophil interaction and formation of neutrophil extracellular traps foster thrombo-inflammatory mechanisms exacerbating the cardiovascular disease course. Therefore, therapies which not only target the clotting mechanisms but simultaneously or independently convey potent cytoprotective effects hemming the inflammatory mechanisms are expected to provide clinical benefits. In this regard, we review the cytoprotective protease activated protein C (aPC) and its strong anti-inflammatory effects thereby preventing the ensuing thrombotic complications in CVD. Furthermore, restoring GAG-like vasculo-protection, such as providing heparin-proteoglycan mimetics to improve regulation of platelet and coagulation activity and to suppress of endothelial perturbance and leukocyte-derived pro-inflammatory cytokines, may provide a path to alleviate thrombo-inflammatory disorders in the future. The vascular tissue-modeled heparin proteoglycan mimic, antiplatelet and anticoagulant compound (APAC), dual antiplatelet and anticoagulant, is an injury-targeting and locally acting arterial antithrombotic which downplays collagen- and thrombin-induced and complement-induced activation and protects from organ injury.

Histon activities in the extracellular environment: regulation and prothrombotic implications

Extracellular DNA and histones as thrombus stabiliser

Modulation of Protein C Activation by Histones, Platelet Factor 4, and Heparinoids

Extracellular DNA and histones: double‐edged swords in immunothrombosis

Extracellular histones in tissue injury and inflammation

Emerging therapeutic strategies targeting extracellular histones for critical and inflammatory diseases: an updated narrative review

Extracellular Histones Trigger Disseminated Intravascular Coagulation by Lytic Cell Death

Neutrophils as instigators of thrombosis: Beyond antimicrobial protection

Release and activity of histone in diseases

Fibrinogen binding to histones in circulation protects against adverse cellular and clinical outcomes

Dysregulated haemostasis in thrombo-inflammatory disease

Abstract 569: Neutrophil Extracellular Traps Promote Thrombin Generation Through Platelet-Dependent and -Independent Mechanisms

Role of Neutrophils and NETs in Animal Models of Thrombosis

Extracellular histones as damage-associated molecular patterns in neuroinflammatory responses

The role of extracellular histone in organ injury

Size‐ and charge‐dependent modulation of the lytic susceptibility and mechanical stability of fibrin‐histone clots by heparin and polyphosphate variants

Mechanisms of pulmonary endothelial permeability and inflammation caused by extracellular histone subunits H3 and H4

Pro-neuroinflammatory and neurotoxic potential of extracellular histones H1 and H3

Thrombosis and Inflammation-A Dynamic Interplay and the Role of Glycosaminoglycans and Activated Protein C

Neutrophil histone modification by peptidylarginine deiminase 4 is critical for deep vein thrombosis in mice

Post-transcriptional control of haemostatic genes: mechanisms and emerging therapeutic concepts in thrombo-inflammatory disorders